Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
Authors:
- Ursula A. MatulonisUMUrsula A. Matulonis
- Sudarshan SharmaSSSudarshan Sharma
- Sharad GhamandeSGSharad Ghamande
- Michael S. GordonMGMichael S. Gordon
- Salvatore A. Del PreteSPSalvatore A. Del Prete
- Isabelle Ray-CoquardIRIsabelle Ray-Coquard
- Elzbieta KutarskaEKElzbieta Kutarska
- Hua LiuHLHua Liu
- Howard FingertHFHoward Fingert
- Xiaofei ZhouXZXiaofei Zhou
- Hadi DanaeeHDHadi Danaee
- Russell J. SchilderRSRussell J. Schilder
- 1 October 2012
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 127 (1) , 63-69
Abstract
No abstract availableKeywords
Funding Information
- Millennium Pharmaceuticals, Inc.
This publication has 22 references indexed in Scilit:
- Functional Significance of Aurora Kinase A Regulatory Interactions with p53–ERα Complex in Human Breast Cancer CellsDiscover Oncology, 2011
- Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?Molecular Cancer Therapeutics, 2010
- Novel strategies for reversing platinum resistanceDrug Resistance Updates, 2009
- Management of Relapsed/Refractory Epithelial Ovarian Cancer: Current Standards and Novel ApproachesTaiwanese Journal of Obstetrics and Gynecology, 2007
- DNA Replication Licensing Factors and Aurora Kinases are Linked to Aneuploidy and Clinical Outcome in Epithelial Ovarian CarcinomaClinical Cancer Research, 2007
- Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian CancerJournal of Clinical Oncology, 2007
- Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group studyGynecologic Oncology, 2006
- Frequent Overexpression of STK15/Aurora-A/BTAK and Chromosomal Instability in Tumorigenic Cell Cultures Derived From Human Ovarian CancerOncology Research, 2005
- A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancerGynecologic Oncology, 2004
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001